QGEN - QIAGEN N.V.
| Previous Close | 41.68 |
| Open | 41.34 |
| Bid | 0.00 x 900 |
| Ask | 42.00 x 900 |
| Day's Range | 41.25 - 41.55 |
| 52 Week Range | 25.04 - 43.16 |
| Volume | 1332540 |
| Avg. Volume | 2,350,292 |
| Market Cap | 9.4B |
| Beta (3Y Monthly) | 0.98 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings Date | Feb 3, 2020 - Feb 7, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.73 |
- Zacks
OSMT vs. QGEN: Which Stock Should Value Investors Buy Now?
OSMT vs. QGEN: Which Stock Is the Better Value Option?
- Zacks
QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus
QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.
- Benzinga
The Daily Biotech Pulse: Tonix Says No Surprises In FDA Meeting Minutes, Aravive Offering, FDA Nod For Qiagen
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 26) Allakos Inc (NASDAQ: ALLK ) Alnylam Pharmaceuticals, ...
- Business Wire
QIAGEN and DiaSorin Receive FDA Approval for The LIAISON QuantiFERON-TB Gold Plus Test on LIAISON Platforms and Begin Commercial Launch
Enabling highly automated screening solution for latent tuberculosis in all throughput segments
- GlobeNewswire
ROSEN, A GLOBAL LAW FIRM, Continues to Investigate Securities Claims Against QIAGEN N.V. – QGEN
NEW YORK, Nov. 25, 2019 -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Qiagen N.V..
- Zacks
QIAGEN Expands Existing Deal With LabCorp for Better Treatment
QIAGEN (QGEN) announces the expansion of partnership with LabCorp (LH) to make genetic information available for clinical and research purposes.
- Business Wire
QIAGEN and LabCorp deepen relationship with widespread use of bioinformatics solutions
Seven-year collaboration expands LabCorp’s use of QIAGEN’s QCI platform with QIAGEN’s Human Gene Mutation Database for rare and hereditary workflows
- Zacks
OSMT or QGEN: Which Is the Better Value Stock Right Now?
OSMT vs. QGEN: Which Stock Is the Better Value Option?
- Benzinga
The Daily Biotech Pulse: Therapix To Reverse Merge With CBD Company, Crispr Gene Editing Therapy Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 18) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
- Zacks
QIAGEN Rides on Solid QuantiFERON-TB Sales Amid Several Woes
QIAGEN (QGEN) pins hopes on its key strategic collaborations with Hamilton Robotics and Tecan for the pre-analytical handling of blood tubes.
- Barrons.com
Dutch Diagnostics Group Qiagen Is Looking Like a Hot Acquisition And Shares Are Soaring
Shares of Dutch genetic testing company Qiagen shot higher on Monday, after the company confirmed it had entered into discussions to “explore potential strategic alternatives” after receiving ”several nonbinding indications of interest.”
- Reuters
Qiagen shares surge as diagnostics group says open to takeover talks
Qiagen NV shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors. The shares had gained 14% on Wednesday, after a report that life sciences tools maker Thermo Fisher Scientific Inc had approached Qiagen about a potential deal. "The Supervisory Board and the Management Board ... are starting discussions with interested parties," the company said on Friday.
- MarketWatch
European stocks tread water after six winning weeks
European stocks on Monday held on to levels they reached after six straight winning weeks, with most of the movement occurring in merger situations.
- Reuters
European shares extend winning streak; Qiagen jumps as company explores sale
European shares edged closer to a record level on Monday, as optimism around U.S.-China trade talks and a surprise move by China's central bank in cutting a key interest rate painted an upbeat picture about global growth. The pan-European STOXX 600 index rose 0.17% by 0814 GMT, extending gains after its six-week winning streak. Also adding to the positive sentiment was news that China's central bank unexpectedly trimmed a closely watched lending rate for the first time in more than four years on Monday, a signal that policymakers are ready to act to prop up slowing growth.
- Investor's Business Daily
Medtech Stock With 28% Gain This Week Confirms It's Fielding Buyout Bids
Dutch genetic-testing company Qiagen confirmed late Friday it's fielding several offers from potential suitors interested in acquiring it. Qiagen stock rose 8.8% on Friday.
- Business Wire
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, and Decides to Enter Into Discussions to Explore Potential Strategic Alternatives
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.
- Reuters
UPDATE 1-Qiagen exploring sale after indications of interest
Qiagen NV said on Friday it has started reviewing options, including sale, after the genetic testing company received several indications of interest for acquisition, sending its U.S. listed shares up 8.5%. The company, which has a market capitalization of $8.6 billion as of Thursday's close, said its management will start talks with interested parties as part of the review. Instruments maker Thermo Fisher Scientific Inc approached Qiagen about a potential deal, Bloomberg reported on Wednesday.
- ACCESSWIRE
QIAGEN receives several conditional, non-binding indications of interest, and decides to enter into discussions to explore potential strategic alterna-tives
VENLO, THE NETHERLANDS / ACCESSWIRE / November 15, 2019 / QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard: QIA) ("QIAGEN" or the "Company") announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.
- Business Wire
QIAGEN Receives Several Conditional, Non-binding Indications of Interest, Enters Into Discussions to Explore Potential Strategic Alternatives
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (“QIAGEN” or the “Company”) announces it has begun a review of potential strategic alternatives after receiving several conditional, non-binding indications of interest for the acquisition of all issued and outstanding shares of the Company. The Supervisory Board and the Management Board of QIAGEN, in accordance with their fiduciary duties and as part of the review of potential strategic alternatives, are starting discussions with interested parties.
- Investor's Business Daily
This Medtech Stock Jumped Bullishly On A Rumored $8 Billion Takeover
Qiagen stock popped in bullish volume Thursday on a report medical technology giant Thermo Fisher Scientific could buy it for $8 billion. It would be one of Thermo Fisher's biggest buys.
- Benzinga
JPMorgan Upgrades Qiagen After Product Surveys, Valuation Analysis
The swing to a bullish rating for Qiagen follows “our recent buy-side survey, two new product surveys, and valuation analysis,” Peterson said in the upgrade note. Barring this, there seems to be potential for the company’s new management team to reset the bar and capitalize on portfolio rationalization and cost reduction opportunities, Peterson mentioned.
- MarketWatch
Qiagen's stock extends surge after J.P. Morgan swings to bullish from bearish
Shares of Qiagen N.V. surged 3.3% in premarket trading Thursday, after J.P. Morgan analyst Tycho Peterson swung to bullish from bearish on the Netherlands-based molecular testing company, citing expectations that company's turnaround will continue. The upgrade comes a day after the stock surged 9.9% after a Bloomberg report that Massachusetts-based analysis and diagnostics company Thermo Fisher Scientific Inc. was considering a buyout of Qiagen, which had a market capitalization of $8.03 billion as of Wednesday's close. J.P. Morgan's Peterson upgraded Qiagen to overweight from underweight and boosted his price target to $40 from $25. "Barring a near-term takeout..., we see potential for new management to reset the bar and pursue abundant opportunities for portfolio rationalization and cost reduction, and therefore we think the worst is in the rearview for [Qiagen]," Peterson wrote in a note to clients. The stock has run up 40% since closing at a 3-year low on Oct. 8 through Wednesday, while the S&P 500 has gained 6.9% over the same time.
- Zacks
QIAGEN (QGEN) Catches Eye: Stock Jumps 9.9%
QIAGEN (QGEN) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
- Bloomberg
Thermo Fisher Considers Buying $8 Billion Diagnostics Firm Qiagen
(Bloomberg) -- Qiagen NV shares jumped the most in 17 years after people with knowledge of the matter said Thermo Fisher Scientific Inc. is considering a takeover of the molecular testing firm.Thermo Fisher has approached the Dutch company about a potential purchase that could become one of its biggest-ever acquisitions, the people said, asking not to be identified because the information is private. Shares of Qiagen rose 13% to 33.20 euros at 1:10 p.m. in Frankfurt, giving it a market value of $8.3 billion. There’s no certainty the deliberations will lead to a transaction, and other bidders for Qiagen could emerge, the people said. Thermo Fisher shares rose 1.4% to $300.02 at the close of New York trading on Wednesday, valuing it at more than $120 billion.The potential transaction could become one of Thermo Fisher’s largest purchases, surpassing its $5 billion takeover of drug-ingredient maker Patheon NV in 2017, according to data compiled by Bloomberg. Its largest acquisition was its $15 billion purchase of Life Technologies Corp. in 2014, the data show.Deal PipelineQiagen spokesman Thomas Theuringer declined to comment, citing company policy. The company serves doctors, researchers and others with molecular-testing platforms that can extract and analyze people’s DNA and RNA. The company emerged from university research and has grown in recent years amid the boom in genetic testing.Representatives for Thermo Fisher, based in Waltham, Massachusetts, couldn’t immediately comment.U.K. scientific measurement testing company LGC Group also has attracted sale interest. The private equity firm Cinven has teamed up with the Abu Dhabi Investment Authority to weigh a joint bid for the KKR & Co.-backed company, people familiar with the matter have said.Leadership ChangeThermo Fisher Chief Executive Officer Marc Casper told analysts last month he feels “great” about the company’s mergers and acquisitions pipeline, which “continues to be very active.”Qiagen CEO Peer Schatz announced last month that he will step down after 27 years at the company, saying it’s time to bring in new leadership. Senior Vice President Thierry Bernard will act as interim CEO until a permanent successor is found. The company also cut its quarterly estimate for sales growth, sending its shares plunging the most in 17 years.Top medical device makers have the capacity to take on additional debt to finance acquisitions, according to Bloomberg Intelligence. Last year, Thermo Fisher rival Medtronic Plc agreed to buy the shares it doesn’t already own in Mazor Robotics Ltd. in a deal valuing the company at about $1.6 billion.(Updates share move in first two paragraphs.)\--With assistance from Aaron Kirchfeld and Tim Loh.To contact the reporters on this story: Ed Hammond in New York at ehammond12@bloomberg.net;Dinesh Nair in London at dnair5@bloomberg.net;Nabila Ahmed in New York at nahmed54@bloomberg.netTo contact the editors responsible for this story: Ben Scent at bscent@bloomberg.net, ;Liana Baker at lbaker75@bloomberg.net, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
